Immatics (NASDAQ:IMTX) Releases Quarterly Earnings Results, Misses Estimates By $0.08 EPS

Immatics (NASDAQ:IMTX) announced its quarterly earnings data on Tuesday. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.08), FiscalAI reports. Immatics had a negative net margin of 572.35% and a negative return on equity of 47.65%. The firm had revenue of $8.81 million for the quarter, compared to the consensus estimate of $9.79 million.

Immatics Trading Up 3.2%

Shares of IMTX traded up $0.35 during mid-day trading on Thursday, reaching $11.14. The company had a trading volume of 116,140 shares, compared to its average volume of 447,425. The stock has a market cap of $1.49 billion, a price-to-earnings ratio of -5.59 and a beta of 1.31. The firm has a fifty day simple moving average of $10.44 and a 200-day simple moving average of $10.15. Immatics has a fifty-two week low of $4.48 and a fifty-two week high of $12.41.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. TD Cowen assumed coverage on Immatics in a research report on Tuesday, April 28th. They set a “buy” rating on the stock. Jefferies Financial Group assumed coverage on Immatics in a research report on Monday, March 16th. They issued a “buy” rating and a $18.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immatics in a research note on Thursday, January 22nd. Wall Street Zen cut Immatics from a “hold” rating to a “sell” rating in a research report on Saturday, May 2nd. Finally, Mizuho set a $25.00 target price on Immatics in a research report on Thursday, February 19th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Immatics has an average rating of “Moderate Buy” and a consensus price target of $19.00.

Hedge Funds Weigh In On Immatics

Hedge funds have recently made changes to their positions in the business. Tudor Investment Corp ET AL purchased a new position in shares of Immatics in the 4th quarter valued at $575,000. Jump Financial LLC purchased a new stake in Immatics during the 4th quarter worth $534,000. Vanguard Personalized Indexing Management LLC increased its stake in Immatics by 3.7% during the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 49,374 shares of the company’s stock worth $518,000 after buying an additional 1,739 shares during the period. Barclays PLC increased its stake in Immatics by 11.4% during the 4th quarter. Barclays PLC now owns 28,185 shares of the company’s stock worth $296,000 after buying an additional 2,874 shares during the period. Finally, The Manufacturers Life Insurance Company increased its stake in Immatics by 18.2% during the 4th quarter. The Manufacturers Life Insurance Company now owns 55,300 shares of the company’s stock worth $557,000 after buying an additional 8,500 shares during the period. Hedge funds and other institutional investors own 64.41% of the company’s stock.

Immatics Company Profile

Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.

At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.